Amgen Inc. (AMGN)
Last Price$318.9(2.6%)
Market Cap$173.1B
AMGN Rating
AMGN Quality rating performance
AMGN Intrinsic Value
Key Highlights:
As of Mar 11, 2025 AMGN Relative Value is $293.1, which is overvalued by 8.1%, compared to current share price of $318.9.
As of Mar 11, 2025 AMGN DCF Value is $606.9, which is undervalued by 90.3%, compared to current share price of $318.9.
AMGN Share Price History
1W 2.1%
1M 8.4%
6M (1.8%)
YTD 11.4%
1Y 19.3%
3Y 53.1%
5Y 87.2%
10Y 178.5%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
AMGN Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$173.1B
$221.2B
$33.4B
$10.4B
Shares Outstanding
543M
Employees
200K
Growth (CAGR)
7.4%
(5.6%)
(10.09%)
173.57%
Profitability
61.5%
21.7%
12.2%
34.4%
31.1%
300.1%
Intrinsic Value
$447.8 (40.4% undervalued)
$603.7
$292.0
$542.3
$1,178.6
58.1%
Return on Capital
Financial Health
$48.1B
4.6x
2.3x
1,022.6%
Dividends
12.1%
2.8%
46.5%
May 16, 2025
Earnings
Aug 04, 2025
BEAT by 2.3%
BEAT by 5.1%
27.0%
9 Beat & 1 Miss
AMGN Stock Financials
AMGN Income Statement Metrics
Annual
Quarterly
LTM
AMGN Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$11.5B +35.6% YoY
Capital Expenditure (CAPEX)
($1,096.0M) -1.4% YoY
Free Cash Flow (FCF)
$10.4B +41.2% YoY
AMGN Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$33.4B 18.6% YoY
Cost of revenue
$12.9B 52.8% YoY
Pre-tax income
$4,609.0M (41.3%) YoY
13.8% margin
AMGN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$91.8B
Current assets ($29.0B, 31.6% of total)
$12.0B (13.0%)
$6,782.0M (7.4%)
Other current assets
$10.3B (11.2%)
Non-current assets ($62.8B, 68.4% of total)
$0.0 (0.0%)
$6,543.0M (7.1%)
$27.7B (30.2%)
Other non-current assets
$28.6B (31.1%)
Financial position
$48.1B
Cash & Short-term
Investments
Total Debt
AMGN Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
AMGN Earnings Surprises
Crunching data... Almost there!
AMGN Dividends
AMGN Dividend Yield
Crunching data... Almost there!
AMGN Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with AMGN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$173.1B | 5.9 | $447.8 40.4% undervalued | 19.3% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$743.9B | 7.0 | $225.3 72.7% overvalued | 12.9% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$398.7B | 5.9 | $197.1 18.9% undervalued | 6.2% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$375.8B | 6.0 | $302.4 41.6% undervalued | 23.2% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$346.3B | 7.1 | $72.1 7.7% overvalued | (40.0%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$240.8B | 7.5 | $112.5 18.8% undervalued | (20.7%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$232.5B | 6.7 | $69.5 6.3% overvalued | 11.9% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$223.3B | 6.6 | $149.6 34.3% undervalued | 9.8% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$148.1B | 6.0 | $25.3 2.7% overvalued | (2.7%) | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$146.8B | 4.7 | $91.4 55.6% undervalued | 25.2% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$143.2B | 6.1 | $91.1 20.4% overvalued | 58.1% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
FAQ
What is Amgen Inc. (AMGN) stock rating?
As of today, Amgen Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Amgen Inc. (AMGN) a good stock to buy?
As of today, Amgen Inc. has a Good stock rating, which is 40.4% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.